Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B

Table 2

Univariate and multivariate analyses of the relationships between biomarker and antiviral therapy indication in the training cohort.

Variables	Univariate	P-value	Multivariate	P-value
PLT	0.989 (0.980-0.998)	0.017	0.992 (0.982-0.102)	0.037
TBil	1.140 (1.048-1.241)	0.002	1.094 (1.006-1.190)	0.035
ALT	1.031 (1.009-1.053)	0.006
AST	1.064 (1.022-1.107)	0.002	1.055 (1.013-1.099)	0.010
GGT	1.051 (1.013-1.090)	0.008
HBeAg	0.996 (0.993-0.999)	0.018

HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; GLB, globulin; ALB, albumin; TBil, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; PT, prothrombin; WBC, white blood count; GR, granulocyte ratio; RBC, lymphocyte ratio, red blood count; Hgb, hemoglobin; PLT, platelet count.